Compare Quest Diagnostics Inc (DGX) vs Intel Corp (INTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Intel Corp — how do they compare? Quest Diagnostics Inc trades at $205.66 (market cap $22.80B), while Intel Corp trades at $100.91 (market cap $541.60B). The key difference: Intel Corp is far larger — about 23.8× Quest Diagnostics Inc's market cap, and Intel Corp pays the higher dividend (2.24%). Which is the better fit depends on your goals.
| DGX | INTC | |
|---|---|---|
Market Cap | $22.80B | $541.60B |
Sector | Health | Technology |
52-Week High | $216.02 | $140.94 |
52-Week Low | $166.42 | $19.31 |
Enterprise Value | $28.82B | $553.84B |
Dividend Yield | 1.67% | 2.24% |
Volume | — | 43,552,012 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Intel (INTC) trades at $103.12, down 6.12% today, as the stock faces technical bearish signals despite recent earnings beats. The company shows mixed fundamentals with negative net income margins and high valuation ratios, though operating cash flow remains strong at $9.7 billion. Recent news highlights Intel's $5.7 billion AI investment in Ireland while analysts express caution about near-term challenges in the semiconductor sector.
Intel presents a complex investment case with improving operational trends but persistent profitability challenges. The stock offers potential upside to the $105.48 consensus target but faces headwinds from competitive pressures and high capital expenditures. Key catalysts include AI execution and PC market recovery, while risks include margin compression and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →
